New Zealand's regulatory approval of Roundup, the herbicide containing glyphosate, rests on industry-funded scientific reviews that now face serious scrutiny. At least one review has been retracted, and others are under active investigation, raising questions about the integrity of the approval process.
Monsanto, now owned by Bayer, funded or shaped the scientific assessments that New Zealand's Environmental Protection Authority relied on to clear Roundup for use. These reviews form the backbone of the herbicide's regulatory standing in the country. The retracted study and ongoing investigations suggest the research underpinning that approval may not meet scientific standards for independence and rigor.
The controversy mirrors broader global concerns about how herbicide safety reviews are conducted. When industry funds the research used to justify its own product's approval, conflicts of interest emerge. Scientists may face pressure, conscious or not, to reach conclusions favorable to the funding source. Peer reviewers and regulators must then assess whether findings reflect genuine science or reflect corporate interests.
New Zealand's situation is particularly consequential because Roundup remains widely used in agriculture and home gardening. Farmers, schools, and households depend on regulatory decisions about the herbicide's safety. If those decisions rest on compromised research, the public health implications extend across multiple sectors.
The investigations and retraction signal that scientific oversight mechanisms are working, at least partially. Peer reviewers identified problems serious enough to warrant retraction. Authorities launched inquiries into other studies. These steps matter because they expose weaknesses in how regulators vet industry-funded research.
Going forward, New Zealand's authorities face a choice. They can demand that herbicide approvals rely primarily on independent, government-funded research free from corporate influence. They can require mandatory disclosure of funding sources in safety reviews. They can strengthen conflict-of-interest policies for scientists conducting regulatory studies.
The case underscores a systemic